electroCore,

electroCore, Operating Cash Flow

The Operating Cash Flow of electroCore, (ECOR) as of Oct 19, 2026 is -8.19 M USD. In the previous year, Operating Cash Flow was -6.95 M USD — a change of 17.83% (lower).

Operating Cash Flow

-8.19 MUSD

YoY

17.83%

Last updated:

Operating Cash Flow of electroCore, is 2025 -8.19 M USD. Operating Cash Flow of electroCore, was 2024 -6.95 M USD. It decreases by 17.83% lower compared to the previous year.

The electroCore, Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-47.11 M USD
Jan 1, 2019
-45.07 M USD
Jan 1, 2020
-20.05 M USD
Jan 1, 2021
-13.63 M USD
Jan 1, 2022
-16.65 M USD
Jan 1, 2023
-14.67 M USD
Jan 1, 2024
-6.95 M USD
Jan 1, 2025
-8.19 M USD
The electroCore, Operating Cash Flow history
YEAROperating Cash FlowYoY
-8.19 MUSD+17.83%
-6.95 MUSD-52.63%
-14.67 MUSD-11.88%
-16.65 MUSD+22.15%
-13.63 MUSD-32.04%
-20.05 MUSD-55.51%
-45.07 MUSD-4.34%
-47.11 MUSD+85.99%
-25.33 MUSD+91.51%
-13.23 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

Operating Cash Flow of electroCore, is -8.19 M USD in 2025.

Operating Cash Flow of electroCore, changed from -6.95 M USD to -8.19 M USD, representing a 17.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow electroCore, since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's electroCore, historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — electroCore,

All Key Metrics — electroCore,